$IPSC

Carr Douglas sold $4K of IPSC

Carr Douglas (SVP Finance & Operations) sold 1,654 shares of Century Therapeutics, Inc. (IPSC) at $2.23 on 2026-06-12.

Original reporting
SEC EDGAR · Carr Douglas
Published Jun 15, 2026, 11:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 11:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IPSC
Neutral
high confidence
Mentioned
$IPSC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IPSCNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, date) by an officer; it may marginally influence sentiment but does not provide new operating or financial information.

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone is unlikely to drive a major repricing.

03

What to watch

Single small sale size and lack of disclosed reason mean traders should avoid extrapolating broader guidance or trial/product changes from this filing alone.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-15 for a sale executed 2026-06-12

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Century Therapeutics, Inc.

Company-level read

Ticker impact

$IPSCNeutralHigh confidence
Context

SEC Form 4 shows Carr Douglas (SVP Finance & Operations) sold 1,654 shares of Century Therapeutics at $2.2320 on 2026-06-12.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted unless part of a broader selling pattern.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and no accompanying fundamental catalyst disclosed in the text.

Market effects

No sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Without a 10b5-1 plan, the sale could reflect liquidity/tax needs rather than bearish fundamentals; impact may be overstated.

Key entities

  • Century Therapeutics, Inc.

    Company whose shares were sold by an officer in the reported Form 4 transaction.

  • Carr Douglas

    SVP Finance & Operations who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IPSCHighAI 8/10

Century Targets FDA Filing for Diabetes Cell Therapy

Century Therapeutics (NASDAQ: IPSC) aims to file for FDA approval of its diabetes cell therapy, CNTY-813, in Q4 2026, with initial human data expected in 2027. The company reported $197.2M in cash as of Q2 2026, sufficient to fund operations into Q1 2029. Preclinical results showed promising glucose control and immune evasion, but clinical outcomes are not guaranteed. Century also advances CNTY-308, a CAR-iT cell therapy, with IND-enabling work on track for 2026. Q2 R&D expenses decreased 27% to

$IPSCMed

Century Therapeutics, Inc. (IPSC): Results of Operations and Financial Condition

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates · Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track f

$AZNMed

Biotech and Pharma Industry News | BioPharma Dive

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

$IPSCMedAI 8/10

New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026

Century Therapeutics (NASDAQ: IPSC) presented new preclinical results for CNTY-813, an iPSC-derived islet replacement engineered with Allo-Evasion™ 5.0, at ADA 2026. The company said transplanted cells maintained normoglycemia for over eight months in mice, with glucose normalization within 60 minutes in glucose tolerance tests. It also reported >50% beta-cell composition, no tumorigenesis in >140 mice, and immune evasion in humanized models without immunosuppression. Century said Phase 1 manufa